<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Heparin Deaths &#187; FDA recall hepain</title>
	<atom:link href="http://heparin-law.com/blog/tag/fda-recall-hepain/feed" rel="self" type="application/rss+xml" />
	<link>http://heparin-law.com/blog</link>
	<description></description>
	<lastBuildDate>Wed, 01 Sep 2010 16:41:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Baxter Having Issues Passing New Heparin-Potency Test</title>
		<link>http://heparin-law.com/blog/2010/03/baxter-having-issues-passing-new-heparin-potency-test.html</link>
		<comments>http://heparin-law.com/blog/2010/03/baxter-having-issues-passing-new-heparin-potency-test.html#comments</comments>
		<pubDate>Tue, 16 Mar 2010 05:47:28 +0000</pubDate>
		<dc:creator>gjohnson</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Baxter heparin]]></category>
		<category><![CDATA[Baxter Heparin Wrongful Death case Illinois]]></category>
		<category><![CDATA[FDA recall hepain]]></category>
		<category><![CDATA[heparin]]></category>
		<category><![CDATA[heparin attorney]]></category>
		<category><![CDATA[Heparin deaths]]></category>

		<guid isPermaLink="false">http://heparin-law.com/blog/?p=443</guid>
		<description><![CDATA[Baxter International, the maker of the blood thinner heparin, says it’s encountering problems having its drug pass a stricter drug-potency test, according to the magazine Modern Healthcare. http://www.modernhealthcare.com/article/20100315/NEWS/303159895 The update that has Baxter troubled has been devised by U.S. Pharmacopeia (USP), and provides potency reading for heparin that are 10 percent greater than the old [...]]]></description>
			<content:encoded><![CDATA[
<p>Baxter International, the maker of the blood thinner heparin, says it’s encountering problems having its drug pass a stricter drug-potency test, according to the magazine Modern Healthcare. <a href="http://www.modernhealthcare.com/article/20100315/NEWS/303159895">http://www.modernhealthcare.com/article/20100315/NEWS/303159895</a></p>
<p>The update that has Baxter troubled has been devised by U.S. Pharmacopeia (USP), and provides potency reading for heparin that are 10 percent greater than the old test.</p>
<p>“It’s taking us a bit longer than anticipated to meet the requirements of the new test,” Baxter spokeswoman Kellie Hotz told Modern Healthcare.</p>
<p>She added that Baxter has been talking to the Food and Drug Administration about way it can meet the new USP standard.</p>
<p>The heparin that is currently being testing is pre-mixed product, not the  concentrated vial product that was investigated by the FDA last year, Hotz told Modern Healthcare.</p>
]]></content:encoded>
			<wfw:commentRss>http://heparin-law.com/blog/2010/03/baxter-having-issues-passing-new-heparin-potency-test.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
